Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label Study to Evaluate the Efficacy and Safety of SCY-078 (Ibrexafungerp) in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment (FURI)

NCT03059992 is registered in ClinicalTrials.gov with Scynexis, Inc. as lead sponsor.

NCT NCT03059992
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03059992 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label Study to Evaluate the Efficacy and Safety of SCY-078 (Ibrexafungerp) in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment (FURI)
Lead sponsor
Scynexis, Inc.
Phase
Phase 3
Overall status
Completed
Start date
April 1, 2017
Completion date
August 25, 2023
Enrollment
233 (actual)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

allergic bronchopulmonary aspergillosis, blastomycosis, chronic pulmonary aspergillosis, coccidioidomycosis, histoplasmosis, invasive candidiasis, invasive pulmonary aspergillosis, mucocutaneous candidiasis, other emerging fungi, recurrent vulvovaginal candidiasis